Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Synonyms
Anagrelide hydrochloride monohydrate
Anagrelide hydrochloride
Anagrelide
Anagrelida
Anagrelidum
Brand Names
Dom-anagrelide
PMS-anagrelide
Agrylin
Mylan-anagrelide
PHL-anagrelide
Sandoz Anagrelide
Xagrid
Anagrelide Mylan
Anagrelide Hydrochloride
Anagrelide
Indication
Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.[L14153]
Categories
Agents producing tachycardia
Antineoplastic Agents
Antineoplastic and Immunomodulating Agents
Antiplatelet agents
Cardiovascular Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 CYP1A2 Inhibitors (weak)
Cytochrome P-450 CYP1A2 Substrates
Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682